<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss</link>
	<title>HSMN NewsFeed</title>
	<description><![CDATA[Healthcare Sales & Marketing Network NewsFeed]]></description>
	<lastBuildDate>Thu, 24 Jul 2008 22:04:58 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/news.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[Inverness Medical Innovations Extends Cardiology Products Distribution Agreement with Thermo Fisher Scientific]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025478</link>
			<pubDate>Thu, 24 Jul 2008 23:49:54 GMT</pubDate>
			<author><![CDATA[Inverness Medical Innovations]]></author>
		 <description><![CDATA[WALTHAM, Mass., July 24  (HSMN NewsFeed)  -- Inverness Medical Innovations, Inc. (Amex: IMA ), a leading manufacturer and marketer of rapid diagnostic products for the consumer and professional markets today announced that it had reached an agreement with ... <br/><font color="red">Diagnositcs, Cardiology, Distribution</font><br/><font color="blue">Inverness Medical Innovations, Thermo Fisher Scientific</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025477</link>
			<pubDate>Thu, 24 Jul 2008 21:40:07 GMT</pubDate>
			<author><![CDATA[Ortho-McNeil-Janssen Pharmaceuticals]]></author>
		 <description><![CDATA[TITUSVILLE, N.J., July 24  (HSMN NewsFeed)  -- Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAX&reg; (topirama... <br/><font color="red">Biopharmaceuticals, FDA, Neurology</font><br/><font color="blue">Ortho-McNeil-Janssen Pharmaceuticals, TOPAMAX, topiramate</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Santhera Receives First Product Approval: Health Canada Approves Catena(R) for Treatment of Friedreich's Ataxia]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025476</link>
			<pubDate>Thu, 24 Jul 2008 21:36:21 GMT</pubDate>
			<author><![CDATA[Santhera Pharmaceuticals]]></author>
		 <description><![CDATA[LIESTAL, SWITZERLAND--Jul 24, 2008 -- Santhera Pharmaceuticals (Swiss:SANN.SW ), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatmen... <br/><font color="red">Biopharmaceuticals, Regulatory, Neurology</font><br/><font color="blue">Santhera Pharmaceuticals, SNT-MC17, idebenone, Catena , Friedreich's Ataxia</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha1-Antitrypsin (AAT) From the European Commission]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025475</link>
			<pubDate>Thu, 24 Jul 2008 21:31:00 GMT</pubDate>
			<author><![CDATA[Talecris Biotherapeutics]]></author>
		 <description><![CDATA[Designation Represents Milestone in Company's Active Aerosol Development Program

RESEARCH TRIANGLE PARK, N.C.--(HSMN NewsFeed)--Talecris Biotherapeutics, Inc. (http://www.talecris.com) announced today that the European Commission followed an opinion of ... <br/><font color="red">Biopharmaceuticals, Regulatory</font><br/><font color="blue">Talecris Biotherapeutics, orphan drug designation, alpha-1 proteinase inhibitor</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Horizon Therapeutics Names Timothy P. Walbert as President and CEO]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025474</link>
			<pubDate>Thu, 24 Jul 2008 21:28:29 GMT</pubDate>
			<author><![CDATA[Horizon Therapeutics]]></author>
		 <description><![CDATA[PALO ALTO, Calif., July 24  (HSMN NewsFeed)  -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Timothy P. Walbert has been named president, chief executive officer and member of the board of directors of Horizo... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Horizon Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medivisor Inc. Announces New Sales and Marketing Agreement for Mucotrol(TM) With Cura Pharmaceutical Co Inc.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025473</link>
			<pubDate>Thu, 24 Jul 2008 21:26:39 GMT</pubDate>
			<author><![CDATA[Medivisor]]></author>
		 <description><![CDATA[HUNTINGTON STATION, NY--Jul 24, 2008 -- Medivisor Inc. (Other OTC:MVSR.PK ) today announced that it has signed a new sales and marketing agreement with Cura Pharmaceutical for the marketing of Mucotrol(TM) in the United States. The groundbreaking drug Muco... <br/><font color="red">Biopharmaceuticals, Drug Delivery</font><br/><font color="blue">Medivisor, Cura Pharmaceutical, Mucotrol</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[NuPathe Inc. Completes $30 Million Series B Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025472</link>
			<pubDate>Thu, 24 Jul 2008 16:28:32 GMT</pubDate>
			<author><![CDATA[NuPathe]]></author>
		 <description><![CDATA[Proceeds Position NuPathe to Progress Its Lead Product, NP101, a Novel Transdermal Patch for Acute Migraine, Pipeline Products, and Development of the Company

CONSHOHOCKEN, Pa.--(HSMN NewsFeed)--NuPathe Inc., a privately held specialty pharmaceutical co... <br/><font color="red">Biopharmaceuticals, Venture Capital</font><br/><font color="blue">NuPathe</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025471</link>
			<pubDate>Thu, 24 Jul 2008 16:15:42 GMT</pubDate>
			<author><![CDATA[PEAK Surgical]]></author>
		 <description><![CDATA[Tissue Dissection System Represents Important Advance in Radiofrequency Surgical Technologies

PALO ALTO, Calif., July 24  (HSMN NewsFeed)  -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a prop... <br/><font color="red">Devices, FDA, Surgery</font><br/><font color="blue">PEAK Surgical, PEAK Surgery System, PULSAR Generator, PlasmaBlade</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Three Novalis Tx(TM) Radiosurgery Platforms Ordered by Top Danish Cancer Hospital]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025470</link>
			<pubDate>Thu, 24 Jul 2008 16:10:44 GMT</pubDate>
			<author><![CDATA[Varian Medical Systems]]></author>
		 <description><![CDATA[COPENHAGEN, Denmark, July 24  (HSMN NewsFeed)  -- Varian Medical Systems (NYSE: VAR ) and BrainLAB AG are announcing that one of Scandinavia's leading cancer centers has ordered three Novalis Tx(TM) radiosurgery platforms which combine the most advanced te... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">Varian Medical Systems, BrainLAB, Novalis Tx, radiosurgery, RapidArc</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cara Therapeutics Secures $12.3 Million in Series C Extension Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025469</link>
			<pubDate>Thu, 24 Jul 2008 15:42:03 GMT</pubDate>
			<author><![CDATA[Cara Therapeutics]]></author>
		 <description><![CDATA[SHELTON, Conn., July 24  (HSMN NewsFeed)  -- Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, De... <br/><font color="red">Biopharmaceuticals, Venture Capital</font><br/><font color="blue">Cara Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Aspect Medical Systems' Letter to the Editor Regarding Anesthesia Awareness Study Published in New England Journal of Medicine]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025468</link>
			<pubDate>Thu, 24 Jul 2008 15:38:51 GMT</pubDate>
			<author><![CDATA[Aspect Medical Systems]]></author>
		 <description><![CDATA[Additional information posted at www.aspectmedical.com

NORWOOD, Mass.--(HSMN NewsFeed)--Aspect Medical Systems (NASDAQ: ASPM ), the global market leader in brain monitoring technology, today announced that the Company’s letter to the editor regarding a ... <br/><font color="red">Devices, Monitoring</font><br/><font color="blue">Aspect Medical Systems, Bispectral Index</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025467</link>
			<pubDate>Thu, 24 Jul 2008 15:32:58 GMT</pubDate>
			<author><![CDATA[Tepha]]></author>
		 <description><![CDATA[LEXINGTON, Mass., July 24  (HSMN NewsFeed)  -- Tepha, Inc., a developer of medical devices derived from a new class of resorbable polymers, announced today that it has appointed John Hartnett to the new position of Executive Vice President and Chief Operat... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">Tepha</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[GE Healthcare to Acquire Vital Signs, Inc., Expanding GE's Monitoring, Anesthesia and Respiratory Care Offerings]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025466</link>
			<pubDate>Thu, 24 Jul 2008 15:28:48 GMT</pubDate>
			<author><![CDATA[GE Healthcare]]></author>
		 <description><![CDATA[CHALFONT ST. GILES, England & TOTOWA, N.J.--(HSMN NewsFeed)--GE Healthcare, a unit of General Electric Company (NYSE:GE ), and Vital Signs, Inc. (NASDAQ:VITL ) announced today that they have entered into a definitive merger agreement for GE to acquire Vita... <br/><font color="red">Devices, Mergers & Acquisitions</font><br/><font color="blue">GE Healthcare, Vital Signs Inc</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Integra LifeSciences Announces Agreement to Acquire Theken Spine]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025465</link>
			<pubDate>Thu, 24 Jul 2008 15:22:42 GMT</pubDate>
			<author><![CDATA[Integra LifeSciences]]></author>
		 <description><![CDATA[PLAINSBORO, N.J., July 24, 2008 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today that it has agreed to acquire Theken Spine, LLC, Theken Disc, LLC and Therics, LLC (together ``Theken'') for $75 million in cash ... <br/><font color="red">Devices, Neurosurgery, Orthopaedic, Mergers & Acquisitions</font><br/><font color="blue">Integra LifeSciences, Theken Spine</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025464</link>
			<pubDate>Thu, 24 Jul 2008 14:21:09 GMT</pubDate>
			<author><![CDATA[STAAR Surgical]]></author>
		 <description><![CDATA[MONROVIA, Calif., July 24  (HSMN NewsFeed)  -- STAAR Surgical Company (Nasdaq: STAA ), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has d... <br/><font color="red">Devices, Ophthalmology, Reimbursement</font><br/><font color="blue">STAAR Surgical, intraocular lens</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Ron Ho Named President and CEO of U-Systems, Inc.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025463</link>
			<pubDate>Wed, 23 Jul 2008 22:31:39 GMT</pubDate>
			<author><![CDATA[U-Systems]]></author>
		 <description><![CDATA[SAN JOSE, Calif.--(HSMN NewsFeed)--U-Systems, the innovative leader in dedicated breast ultrasound systems, has appointed Ron Ho as President & Chief Executive Officer.

As a recognized business leader, Ho brings in more than 20 years of executive manage... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">U-Systems, breast ultrasound</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025462</link>
			<pubDate>Wed, 23 Jul 2008 22:28:08 GMT</pubDate>
			<author><![CDATA[Pioneer Surgical Technology]]></author>
		 <description><![CDATA[Next generation design reduces the amount of retraction needed for surgical implantation

MARQUETTE, Mich., July 23  (HSMN NewsFeed)  -- Pioneer Surgical Technology today announces the market availability of the SlimFuse(TM) Anterior Cervical Plate Syste... <br/><font color="red">Devices, Orthopaedic, Neurosurgery</font><br/><font color="blue">Pioneer Surgical Technology, SlimFuse, Cervical Plate</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Vaccine Executive Staph Bakali Joins Genocea Biosciences' Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025461</link>
			<pubDate>Wed, 23 Jul 2008 22:25:23 GMT</pubDate>
			<author><![CDATA[Genocea Biosciences]]></author>
		 <description><![CDATA[Director at Intercell AG and Former COO of ID Biomedical brings 20 years of vaccine development and management expertise

CAMBRIDGE, Mass.--(HSMN NewsFeed)--Genocea Biosciences, a leading vaccine discovery and development company, today announced that it... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Genocea Biosciences</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Hospitals and Healthcare Providers to Save with Premier Invasive Hemodynamic Monitoring Products Agreements]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025460</link>
			<pubDate>Wed, 23 Jul 2008 13:57:21 GMT</pubDate>
			<author><![CDATA[Premier Purchasing]]></author>
		 <description><![CDATA[CHARLOTTE, N.C.--(HSMN NewsFeed)--Premier Purchasing Partners, LP, today announced new agreements for invasive hemodynamic monitoring products and accessories have been awarded to Edwards Lifesciences LLC of Irvine, Calif.; Hospira Worldwide Inc. of Lake F... <br/><font color="red">Devices, Group Purchasing</font><br/><font color="blue">Premier Purchasing, Edwards Lifesciences, Hospira, Pulsion Medical</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Tengion Appoints Mark Stejbach Vice President of Marketing and Commercial Planning]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025459</link>
			<pubDate>Wed, 23 Jul 2008 13:54:53 GMT</pubDate>
			<author><![CDATA[Tengion]]></author>
		 <description><![CDATA[EAST NORRITON, Pa., July 23  (HSMN NewsFeed)  -- Tengion Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, today announced that it has appointed Mark Stejbach as Vice President, Marketing and Commercial ... <br/><font color="red">Regenerative Medicine, Personnel</font><br/><font color="blue">Tengion</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Palomar Medical Expands Its Product Portfolio Through a Distribution Agreement with Astron Clinica]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025458</link>
			<pubDate>Wed, 23 Jul 2008 13:52:49 GMT</pubDate>
			<author><![CDATA[Palomar Medical Technologies]]></author>
		 <description><![CDATA[BURLINGTON, Mass., July 23  (HSMN NewsFeed)  -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI ), a leading researcher and developer of light-based systems for cosmetic treatments, announced today that it has entered into a Distribution Agreement with As... <br/><font color="red">Devices, Dermatology, Distribution</font><br/><font color="blue">Palomar Medical Technologies, Astron Clinica</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025457</link>
			<pubDate>Wed, 23 Jul 2008 13:50:24 GMT</pubDate>
			<author><![CDATA[Bristol-Myers Squibb]]></author>
		 <description><![CDATA[PRINCETON, N.J. & LONDON--(HSMN NewsFeed)--Bristol-Myers Squibb Company (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on June 30th and validation of a... <br/><font color="red">Biopharmaceuticals, FDA, Endocrinology</font><br/><font color="blue">Bristol-Myers Squibb, AstraZeneca, ONGLYZA, saxagliptin, diabetes</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025456</link>
			<pubDate>Wed, 23 Jul 2008 13:43:51 GMT</pubDate>
			<author><![CDATA[Bradmer Pharmaceuticals]]></author>
		 <description><![CDATA[TORONTO, July 23  (HSMN NewsFeed)  - July 23, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR ), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has initiated enrollment in the Phase... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Bradmer Pharmaceuticals, GLASS-ART Trial, Neuradiab, glioblastoma multiforme</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affairs]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025455</link>
			<pubDate>Wed, 23 Jul 2008 13:40:24 GMT</pubDate>
			<author><![CDATA[MAP Pharmaceuticals]]></author>
		 <description><![CDATA[MOUNTAIN VIEW, Calif., July 23  (HSMN NewsFeed)  -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced the appointment of Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Medical Affairs.

Dr. Keller... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">MAP Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Depomed's ProQuin(R) XR Achieves First Marketing Authorization in Europe]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025454</link>
			<pubDate>Wed, 23 Jul 2008 13:38:16 GMT</pubDate>
			<author><![CDATA[Depomed]]></author>
		 <description><![CDATA[ProQuin XR is licensed for Europe to Rottapharm/Madaus

MENLO PARK, Calif.--(HSMN NewsFeed)--Depomed, Inc. (NASDAQ:DEPO ) and Rottapharm|Madaus announced today that the Marketing Authorization (MA) for ProQuin XR has been received from the Medical Produc... <br/><font color="red">Biopharmaceuticals, Regulatory</font><br/><font color="blue">Depomed, ProQuin XR, ciprofloxacin, Rottapharm</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AngioDynamics Appoints Vice President of International IRE Sales]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025453</link>
			<pubDate>Wed, 23 Jul 2008 13:36:08 GMT</pubDate>
			<author><![CDATA[AngioDynamics]]></author>
		 <description><![CDATA[QUEENSBURY, N.Y.--(HSMN NewsFeed)--AngioDynamics, Inc. (NASDAQ:ANGO ), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular d... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">AngioDynamics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teva Completes Acquisition of Bentley Pharmaceuticals]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025452</link>
			<pubDate>Wed, 23 Jul 2008 13:33:23 GMT</pubDate>
			<author><![CDATA[Teva Pharmaceutical]]></author>
		 <description><![CDATA[Teva Gains a Strong Platform to Become a Leading Player in Spain

JERUSALEM--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) announced today that it has completed its acquisition of Bentley Pharmaceuticals, Inc. (NYSE: BNT ), which w... <br/><font color="red">Biopharmaceuticals, Generics, Mergers & Acquisitions</font><br/><font color="blue">Teva Pharmaceutical, Bentley Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Tomas Leanderson appointed new President and CEO for Active Biotech]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025451</link>
			<pubDate>Wed, 23 Jul 2008 13:31:22 GMT</pubDate>
			<author><![CDATA[Active Biotech]]></author>
		 <description><![CDATA[LUND, SWEDEN--Jul 23, 2008 -- Sven Andr&eacute;asson has notified the Board of his wish to resign from the position as President & CEO of Active Biotech AB.

Sven Andr&eacute;asson has been the company's CEO since 1999 and under his leadership Active Bio... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Active Biotech</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025450</link>
			<pubDate>Wed, 23 Jul 2008 13:27:49 GMT</pubDate>
			<author><![CDATA[ARIUS Research]]></author>
		 <description><![CDATA[BASEL, Switzerland and TORONTO, July 23  (HSMN NewsFeed)  - Roche (SWX: ROG ) and ARIUS Research Inc. (TSX:ARI ) today announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of a... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">ARIUS Research, Roche Group</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CryoCath Arctic Front(R) Results Published in JACC]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025449</link>
			<pubDate>Tue, 22 Jul 2008 21:56:06 GMT</pubDate>
			<author><![CDATA[CryoCath Technologies]]></author>
		 <description><![CDATA[Strong efficacy results from a multi-center 293-patient European
trial

MONTREAL, July 22  (HSMN NewsFeed)  - CryoCath&reg; Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that results previousl... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">CryoCath Technologies, Arctic Front, cryoablation, Atrial Fibrillation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Starion Instruments Signs Distribution Agreement With Datascope for Tissue Welding Technology]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025448</link>
			<pubDate>Tue, 22 Jul 2008 21:48:05 GMT</pubDate>
			<author><![CDATA[Starion Instruments]]></author>
		 <description><![CDATA[Agreement Reinforces Starion's Leadership Position in the Cardiac Marketplace

SUNNYVALE, Calif., July 22  (HSMN NewsFeed)  -- Starion Instruments, a leading surgical device company, today announced a non-exclusive distribution agreement with Datascope C... <br/><font color="red">Devices, Distribution</font><br/><font color="blue">Starion Instruments, Datascope, Tissue Welding</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Hospitals and Healthcare Providers to Save with Premier Sterilization Wrap Agreement]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025447</link>
			<pubDate>Tue, 22 Jul 2008 21:42:21 GMT</pubDate>
			<author><![CDATA[Premier Purchasing]]></author>
		 <description><![CDATA[CHARLOTTE, N.C.--(HSMN NewsFeed)--Premier Purchasing Partners, LP, today announced a new agreement for sterilization wrap has been awarded to supplier Kimberly-Clark.

The 36-month agreement, effective September 1, 2008 is available to acute care and con... <br/><font color="red">Devices, Group Purchasing</font><br/><font color="blue">Premier Purchasing, Kimberly-Clark</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025446</link>
			<pubDate>Tue, 22 Jul 2008 21:38:57 GMT</pubDate>
			<author><![CDATA[Cell Genesys]]></author>
		 <description><![CDATA[SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Cell Genesys, Inc. (Nasdaq:CEGE ) announced today the publication of final data from the second of two Phase 2 clinical trials (G-0010) of GVAX immunotherapy for prostate cancer in the online issue of Cancer, a... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Cell Genesys, G-0010, GVAX immunotherapy, prostate cancer</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[EKOS(R) Introduces New EkoSonic(TM) Endovascular System With Rapid Pulse(TM) Modulation Technology - Four Times Faster Than Conventional Catheter-Directed Thrombolysis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025445</link>
			<pubDate>Tue, 22 Jul 2008 21:26:54 GMT</pubDate>
			<author><![CDATA[EKOS Corp]]></author>
		 <description><![CDATA[With No Evidence of Thrombus Breakage or Hemolysis

BOTHELL, Wash.--(HSMN NewsFeed)--EKOS Corporation announced today the launch of the EkoSonic™ Endovascular System (EkoSonic ES) with Rapid Pulse Modulation (RPM) for the dissolution of vascular blood cl... <br/><font color="red">Devices, Interventional</font><br/><font color="blue">EKOS Corp, EkoSonic ES</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Response Biomedical Receives US FDA Clearance for RAMP(R) NT-proBNP Test for Diagnosis of Heart Failure]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025444</link>
			<pubDate>Tue, 22 Jul 2008 21:21:02 GMT</pubDate>
			<author><![CDATA[Response Biomedical]]></author>
		 <description><![CDATA[VANCOUVER, July 22  (HSMN NewsFeed)  - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to market the RAMP&reg; NT-proBNP Test as an aid to the rap... <br/><font color="red">Diagnostics, Cardiology, FDA</font><br/><font color="blue">Response Biomedical, RAMP NT-proBNP</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Nosocomial Vaccines - Minefield or Goldmine?]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025443</link>
			<pubDate>Tue, 22 Jul 2008 15:51:27 GMT</pubDate>
			<author><![CDATA[Datamonitor]]></author>
		 <description><![CDATA[London, July 22, 2008--(HSMN NewsFeed)--Over the last decade, Staphylococcus aureus (S. aureus) bacteria have become a key concern in both the hospital and community setting. The increasing spread of resistant strains such as MRSA underlines the urgent nee... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Datamonitor, vaccine, nosocomial</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[K2M Launches RANGE Rigid Rod (R2 Rod) for Complex Procedures]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025442</link>
			<pubDate>Tue, 22 Jul 2008 15:07:24 GMT</pubDate>
			<author><![CDATA[K2M]]></author>
		 <description><![CDATA[Cobalt Chrome Alloy Rod Provides a Unique Implant Addition to the RANGE Spinal System

LEESBURG, Va.--(HSMN NewsFeed)--K2M, Inc., the spinal device company developing innovative and simplified solutions for the treatment of complex spinal pathologies and... <br/><font color="red">Devices, Orthopaedic, Neurosurgery</font><br/><font color="blue">K2M, RANGE Rigid Rod, R2 Rod, spine surgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Xanodyne Receives Approvable Letter From the U.S. Food and Drug Administration for ZIPSOR(TM) (diclofenac potassium) Capsules]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025441</link>
			<pubDate>Tue, 22 Jul 2008 14:58:25 GMT</pubDate>
			<author><![CDATA[Xanodyne Pharmaceuticals]]></author>
		 <description><![CDATA[New Product Candidate for Pain

NEWPORT, Ky.--(HSMN NewsFeed)--Xanodyne Pharmaceuticals, Inc. announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zipsor, its candidate for the treatment of patien... <br/><font color="red">Biopharmaceuticals, FDA</font><br/><font color="blue">Xanodyne Pharmaceuticals, Zipsor, diclofenac</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Vascular Therapies LLC Appoints Samuel M. Liang as President and Chief Executive Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025440</link>
			<pubDate>Tue, 22 Jul 2008 13:39:07 GMT</pubDate>
			<author><![CDATA[Vascular Therapies LLC]]></author>
		 <description><![CDATA[CRESSKILL, N.J., July 22, 2008 (PRIME NEWSWIRE) -- Vascular Therapies LLC, a vascular combination device company, today announced that it has appointed Samuel M. Liang as President and Chief Executive Officer effective immediately. Sriram S. Iyer, M.D., th... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">Vascular Therapies LLC</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025439</link>
			<pubDate>Tue, 22 Jul 2008 13:36:48 GMT</pubDate>
			<author><![CDATA[Santarus]]></author>
		 <description><![CDATA[Santarus to sponsor conference call at 10:00 a.m. Eastern time today

SAN DIEGO & MENLO PARK, Calif.--(HSMN NewsFeed)--Santarus, Inc. (NASDAQ: SNTS ) and Depomed, Inc. (NASDAQ: DEPO ) today announced that they have entered into a promotion agreement gran... <br/><font color="red">Biopharmaceuticals, Endocrinology</font><br/><font color="blue">Santarus, Depomed, GLUMETZA, metformin, diabetes</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[PhiloGene, Inc. Announces that VEGFb(TM) has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025438</link>
			<pubDate>Tue, 22 Jul 2008 13:33:34 GMT</pubDate>
			<author><![CDATA[PhiloGene]]></author>
		 <description><![CDATA[SUMMIT, N.J.--(HSMN NewsFeed)--PhiloGene, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to VEGFb for the treatment of patients with advanced melanoma. This approval is for a larger subset of melanoma pa... <br/><font color="red">Biopharmaceuticals, FDA, Oncology</font><br/><font color="blue">PhiloGene, orphan drug designation, VEGFb, melanoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025437</link>
			<pubDate>Tue, 22 Jul 2008 13:30:08 GMT</pubDate>
			<author><![CDATA[Biogen Idec]]></author>
		 <description><![CDATA[TYSABRI's Benefits Continue to Drive Product's Growth with More Than 31,800 Patients Receiving Treatment

CAMBRIDGE, Mass. & DUBLIN, Ireland--(HSMN NewsFeed)--Biogen Idec (NASDAQ: BIIB ) and Elan Corporation, plc (NYSE: ELN ) today announced the two-year... <br/><font color="red">Biopharmaceuticals, Neurology</font><br/><font color="blue">Biogen Idec, Elan Corp, TYSABRI, natalizumab, multiple sclerosis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ev3 Inc. Announces Promotion of Pascal E.R. Girin to Lead Global Neurovascular Business and International]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025436</link>
			<pubDate>Mon, 21 Jul 2008 21:23:23 GMT</pubDate>
			<author><![CDATA[ev3]]></author>
		 <description><![CDATA[PLYMOUTH, Minn., July 21  (HSMN NewsFeed)  -- ev3 Inc. (Nasdaq: EVVV ) today announced that effective July 18, 2008, Pascal E.R. Girin was promoted to Executive Vice President of ev3 Inc. and President, Worldwide Neurovascular and International. In this ne... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">ev3</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025435</link>
			<pubDate>Mon, 21 Jul 2008 19:36:01 GMT</pubDate>
			<author><![CDATA[Prof Terje Pedersen]]></author>
		 <description><![CDATA[LONDON, July 21  (HSMN NewsFeed)  -- The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with... <br/><font color="red">Biopharmaceuticals, Cardiology</font><br/><font color="blue">SEAS study, aortic stenosis, Merck, Schering-Plough, simvastatin, ezetimibe</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Clears Osmetech's Warfarin Sensitivity Test and New eSensor(R) XT-8 Platform]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025434</link>
			<pubDate>Mon, 21 Jul 2008 19:30:09 GMT</pubDate>
			<author><![CDATA[Osmetech]]></author>
		 <description><![CDATA[PASADENA, Calif.--(HSMN NewsFeed)--Osmetech plc (AIM:OMH), the fast growing international molecular diagnostics company, announces that it has received 510(k) clearance from the US Food & Drug Administration (‘FDA’) for its eSensor Warfarin Sensitivity Tes... <br/><font color="red">Diagnostics, FDA</font><br/><font color="blue">Osmetech, Warfarin Sensitivity Test</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Inion Receives 510(k) Marketing Clearance to Sell its Biodegradable Graft Containment Systems in the USA for Spinal Fusion Procedures]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025433</link>
			<pubDate>Mon, 21 Jul 2008 15:20:26 GMT</pubDate>
			<author><![CDATA[ Inion]]></author>
		 <description><![CDATA[TAMPERE, Finland and GUILDFORD, England, July 21  (HSMN NewsFeed)  -- Inion (LSE: IIN ), the company focused on the development and commercialisation of novel biodegradable medical implants, today announces it has received 510(k) marketing clearance from t... <br/><font color="red">Devices, Orthopaedic, Neurosurgery, FDA</font><br/><font color="blue"> Inion, Cervical Fusion, Thoraco-Lumbar Fusion, spine surgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Genentech Announces Receipt of Proposal From Roche]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025432</link>
			<pubDate>Mon, 21 Jul 2008 15:17:40 GMT</pubDate>
			<author><![CDATA[Genentech]]></author>
		 <description><![CDATA[SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc. (NYSE:DNA ) announced today that it has received a proposal from Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89.00 in cash per share. Curr... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Genentech, Roche Group</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[First U.S. Patient Undergoes Non-Invasive Magnetic Resonance-Guided Focused Ultrasound Procedure to Relieve Pain From Bone Metastases]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025431</link>
			<pubDate>Mon, 21 Jul 2008 15:15:07 GMT</pubDate>
			<author><![CDATA[InSightec]]></author>
		 <description><![CDATA[Experimental Procedure Performed as Part of a Large U.S. Clinical Trial

TIRAT CARMEL, Israel, July 21  (HSMN NewsFeed)  -- InSightec Ltd. announced today that the first U.S. patient has been treated in the company's pivotal trial to evaluate the safety ... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">InSightec, ExAblate, Focused Ultrasound</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Insmed Provides Update on IPLEX(TM) Programs]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025430</link>
			<pubDate>Mon, 21 Jul 2008 15:12:41 GMT</pubDate>
			<author><![CDATA[Insmed]]></author>
		 <description><![CDATA[MMD Phase 2 Trial Fully Enrolled

Expanded Access Program Generates $4.9 Million in Cost Recovery During First Half of 2008

RICHMOND, Va., July 21  (HSMN NewsFeed)  -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics (FOBs) and biopha... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Insmed,  IPLEX, Muscular Dystrophy, Amyotrophic Lateral Sclerosis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[IMI Intelligent Medical Implants AG Announces the Appointment Robert J. Hill as Vice President of Operations]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025429</link>
			<pubDate>Mon, 21 Jul 2008 15:08:49 GMT</pubDate>
			<author><![CDATA[Intelligent Medical Implants]]></author>
		 <description><![CDATA[ZUG, Switzerland, July 21  (HSMN NewsFeed)  -- IMI Intelligent Medical Implants AG (&quot;IMI&quot;) announced today that it has appointed Robert J. Hill as Vice President of Operations.

&quot;I have worked with Bob in the past and am extremely happy th... <br/><font color="red">Devices, Ophthalmology, Personnel</font><br/><font color="blue">Intelligent Medical Implants, Retinal Implant</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025428</link>
			<pubDate>Mon, 21 Jul 2008 15:06:46 GMT</pubDate>
			<author><![CDATA[Mylan]]></author>
		 <description><![CDATA[PITTSBURGH, July 21  (HSMN NewsFeed)  -- Mylan Inc. (NYSE: MYL ) announced today the appointment of Daniel E. Crookshank as vice president - Investor Relations and as a member of the company's senior leadership team. Reporting to Chief Financial Officer Ed... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Mylan</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bristol-Myers Squibb Names Chief Procurement Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025427</link>
			<pubDate>Mon, 21 Jul 2008 13:03:59 GMT</pubDate>
			<author><![CDATA[Bristol-Myers Squibb]]></author>
		 <description><![CDATA[NASSAU PARK, N.J.--(HSMN NewsFeed)--Bristol-Myers Squibb Company (NYSE:BMY ) today announced that Quentin Roach has been named senior vice president and chief procurement officer. In this role, Roach will be responsible for global leadership for supplier r... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Bristol-Myers Squibb</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[iCAD Completes Acquisition of CAD Sciences]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025426</link>
			<pubDate>Mon, 21 Jul 2008 13:02:00 GMT</pubDate>
			<author><![CDATA[ iCAD]]></author>
		 <description><![CDATA[NASHUA, N.H., July 21  (HSMN NewsFeed)  -- iCAD, Inc. (Nasdaq: ICAD ), an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced the completion of its previously announced agreement to purchase the principal assets of CAD Sc... <br/><font color="red">Devices, Radiology, Mergers & Acquisitions</font><br/><font color="blue"> iCAD , CAD Sciences</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025425</link>
			<pubDate>Mon, 21 Jul 2008 12:57:17 GMT</pubDate>
			<author><![CDATA[Roche Group]]></author>
		 <description><![CDATA[Combination to enhance innovation by allowing for diversity of research approaches while also encouraging sharing of IP, technologies, partnerships and other key assets

Improved operational efficiency to result from reduced complexity, elimination of du... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Roche Group, Genentech</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025424</link>
			<pubDate>Mon, 21 Jul 2008 12:51:35 GMT</pubDate>
			<author><![CDATA[BARRX Medical]]></author>
		 <description><![CDATA[Long-term study confirms treatment could help 3.3 million U.S. sufferers

SUNNYVALE, California, July 21  (HSMN NewsFeed)  -- BARRX Medical, Inc. today announced that 98.4 percent of patients having a precancerous condition of their esophagus called Barr... <br/><font color="red">Devices, Gastroenterology</font><br/><font color="blue">BARRX Medical, Barrett's esophagus, HALO ablation system, HALO360</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AcuNetx Announces Change in Management Lineup]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025423</link>
			<pubDate>Fri, 18 Jul 2008 19:47:16 GMT</pubDate>
			<author><![CDATA[AcuNetx]]></author>
		 <description><![CDATA[TORRANCE, Calif.--(HSMN NewsFeed)--AcuNetx Inc. (OTCBB:ANTX ) today announced that it had accepted the resignation of Ronald A. Waldorf, President and CEO of the company. In a letter to the company’s Board, Mr. Waldorf stated that “It is with a heavy heart... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">AcuNetx</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Advanced Bionics Reaches Resolution With FDA, Settles Financial Suit]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025422</link>
			<pubDate>Fri, 18 Jul 2008 19:44:45 GMT</pubDate>
			<author><![CDATA[Advanced Bionics]]></author>
		 <description><![CDATA[VALENCIA, Calif., July 18  (HSMN NewsFeed)  -- Advanced Bionics agreed to settle an administrative complaint arising from a disagreement with the U.S. Food and Drug Administration (FDA). The FDA asserted that Advanced Bionics should have made a formal subm... <br/><font color="red">Devices, FDA, Litigation</font><br/><font color="blue">Advanced Bionics, HiRes90K, cochlear implant</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[minSURG(TM) Corporation Launches International Division]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025421</link>
			<pubDate>Fri, 18 Jul 2008 15:36:16 GMT</pubDate>
			<author><![CDATA[minSURG]]></author>
		 <description><![CDATA[CLEARWATER, Fla., July 18  (HSMN NewsFeed)  -- minSURG Corporation, producers of the TruFUSE&reg; percutaneous facet stabilization procedure, announced today the creation of minSURG International, Incorporated. The international division has been establish... <br/><font color="red">Devices, Orthopaedic, Neurosurgery</font><br/><font color="blue">minSURG, TruFUSE, spine surgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[DUSA Announces Update on Nicomide(R) Status]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025420</link>
			<pubDate>Fri, 18 Jul 2008 15:31:55 GMT</pubDate>
			<author><![CDATA[DUSA Pharmaceuticals]]></author>
		 <description><![CDATA[WILMINGTON, MASSACHUSETTS--Jul 18, 2008 -- DUSA Pharmaceuticals, Inc.&reg; (NASDAQ GM: DUSA) reported today that Nicomide&reg;, a vitamin-mineral product currently prescribed by dermatologists, will no longer be manufactured and marketed as a prescription ... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">DUSA Pharmaceuticals, Nicomide</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[SyntheMed Appoints Corinne Mundin as Director, International Market Development]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025419</link>
			<pubDate>Fri, 18 Jul 2008 15:29:38 GMT</pubDate>
			<author><![CDATA[SyntheMed]]></author>
		 <description><![CDATA[ISELIN, N.J., July 18  (HSMN NewsFeed)  -- SyntheMed, Inc. (OTC Bulletin Board: SYMD ), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today the appoin... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">SyntheMed</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Power Medical Interventions, Inc. Announces the Successful Demonstration of Incision-Free Bowel Resection and Anastomosis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025418</link>
			<pubDate>Fri, 18 Jul 2008 14:47:38 GMT</pubDate>
			<author><![CDATA[Power Medical Interventions]]></author>
		 <description><![CDATA[Successful Resection and Anastomosis via the Colon Opens New Techniques for Widespread Adoption of Incision-Free NOTES Surgery

LANGHORNE, Pa., July 18, 2008 (PRIME NEWSWIRE) -- Power Medical Interventions(r), Inc. (NasdaqGM:PMII ), a leader in developin... <br/><font color="red">Devices, Surgery</font><br/><font color="blue">Power Medical Interventions, Intelligent Surgical Instruments, NOTES surgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teva to Acquire Barr]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2025417</link>
			<pubDate>Fri, 18 Jul 2008 14:43:51 GMT</pubDate>
			<author><![CDATA[Teva Pharmaceutical]]></author>
		 <description><![CDATA[Significantly Strengthens Teva's Market Leadership Position in the U.S. and in Key Global Markets

Acquisition Expected to Be Accretive in the Fourth Quarter after Closing

JERUSALEM & MONTVALE, N.J.--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Teva Pharmaceutical, Barr Pharmaceuticals</font>]]>
			</description>
	</item>
	</channel>
</rss>